Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation

Trial Profile

Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Olmutinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.
    • 16 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Interim results (n = 76) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology. (As of 30th Nov 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top